



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michelle Schaffer Docket No.: 39766-0129A
Serial No.: 10/066,009 Group Art Unit: 1652
Filing Date: February 1, 2002 Examiner: Nashed, Nashaat T.

For: **CRYSTALLIZATION OF IGF**
Express Mail Label No.: EL 993 690 340 US
Mailing Date: December 7, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

BEST AVAILABLE COPY

12/14/2004 RHEBRAHT 00000002 081641 10066009
02 FC:1806 180.00 DA

- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39766-0129A).

Respectfully submitted,

Dated: December 7, 2004

By: _____

Ginger R. Dreger
Reg. No. 33,055

HELLER EHRMAN WHITE & MCAULIFFE LLP
Customer No. 25213
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-063

**INFORMATION DISCLOSURE
STATEMENT**

PTO-1449

ATTY. DOCKET NO.:

39766-0129A

SERIAL NO.:

10/066,009

APPLICANT : Michelle Schaffer

FILING DATE: 2/1/2002

GROUP: 1652

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE


FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	668,914	30.08.95	EP			<input type="checkbox"/>	<input type="checkbox"/>
	00/23469	27.04.00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	91/03253	21.03.91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	92/11865	23.07.92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	93/08826	13.05.93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	93/23067	25.11.93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	93/23071	25.11.93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	93/25219	23.12.93	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Cavanagh, et al., <u>Protein NMR Spectroscopy: Principles and Practice</u> , New York Academic Press, Inc., pps. 447-451, 478-518 and 525-528 (1996).
	Van Wyk, et al., "The Somatomedins: A Family of Insulinlike Hormones under Growth Hormone Control", <u>Recent Prog. Horm. Res.</u> , 30:259-318 (1974).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1869R1Serial No.
10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Schaffer, M. et al.Filing Date
01 Feb 2002Group
NOT KNOWN

DEC 07 2004

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
	36 668,914	30.08.95	EP			
	37 WO 00/23469	27.04.00	PCT			
	38 WO 91/03253	21.03.91	PCT			
	39 WO 92/11465	23.07.92	PCT			
	40 WO 93/08826	13.05.93	PCT			
	41 WO 93/23067	25.11.93	PCT			
	42 WO 93/23071	25.11.93	PCT			
	43 WO 93/25219	23.12.93	PCT			
NE	44 WO 94/04569	03.03.94	PCT			
NE	45 WO 94/16722	04.08.94	PCT			
NE	46 WO 96/01124	18.01.96	PCT			
NE	47 WO 96/33216	24.10.96	PCT			
NE	48 WO 97/00895	09.01.97	PCT			
NE	49 WO 98/45427	15.10.98	PCT			
NE	50 WO 99/01476	14.01.99	PCT			
NE	51 WO 99/38011	29.07.99	PCT			

References are not
in the file

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

NE	52	Adams et al., "Structure of Rhombohedral 2 Zinc Insulin Crystals." <u>Nature</u> , 224:491-495 (Nov 1969)
NE	53	Bach and Rechler., "Insulin-Like Growth Factor Binding Proteins." <u>Diabetes Reviews</u> , 3(1):38-61 (1995)
NE	54	Baker et al., "Role of Insulin-Like Growth Factors in Embryonic and Postnatal Growth." <u>Cell</u> , 75:73-82 (Oct 1993)
NE	55	Ballard et al., "Does IGF-I Ever Act Through the Insulin Receptor?" <u>The Insulin-Like Growth Factors and Their Regulatory Proteins</u> , Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994)
NE	56	Bar et al., "Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I." <u>Endocrinology</u> , 127(6):3243-3245 (1990)
NE	57	Barinaga, M., "Neurotrophic Factors Enter the Clinic [News]." <u>Science</u> , 264:772-774 (1994)
NE	58	Baserga., "The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (Jan 1995)
NE	59	Baxter, "Physiological Roles of IGF Binding Proteins" <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, eds., Elsevier, New York pps. 371-380 (1991)
NE	60	Baxter., "The Somatomedins: Insulin-Like Growth Factors." <u>Advances in Clinical Chemistry</u> , 25:49-115 (1986)
NE	61	Bayne et al., "Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor." <u>J. Bio. Chem.</u> 263:6233-6239 (1988)

Examiner

A. Shed 6/4/04

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066.009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

NE	62	Bayne et al., "The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor." <u>J. Bio. Chem.</u> 264(19):11004-11008 (1988)
NE	63	Bayne et al., "The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type I Insulin-Like Growth Factor Receptor." <u>J. Bio. Chem.</u> 265(26):15648-15652 (Sep 15, 1990)
NE	64	Binoux, M., "Recent Data on Somatomedins (Insulin-Like Growth Factors)." <u>Annales d'Endocrinologie</u> (English Abstract Included) 41:157-192 (1980)
NE	65	Blundell et al., "Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding." <u>Proc. Natl. Acad. Sci. USA</u> 75(1):180-184 (Jan 1978)
NE	66	Blundell et al., "Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors." <u>Federation Proc.</u> 42:2592-2597 (1983)
NE	67	Bondy, C., "Clinical Uses of Insulin-Like Growth Factor I." <u>Annals of Internal Medicine</u> , 120:593-601 (1994)
NE	68	Buckbinder et al., "Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53." <u>Nature</u> , 377:646-649 (Oct 1995)
NE	69	Cascieri et al., "Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor." <u>Biochemistry</u> 27(9):3229-3233 (May 3, 1988)
NE	70	Cascieri et al., "Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors." <u>J. Bio. Chem.</u> 264:2199-2202 (1989)
NE		Cavanagh et al., Protein NMR Spectroscopy: Principles and Practice., New York:Academic Press, Inc., (1996) No reference
NE	72	Clemmons and Van Wyk., "Somatomedin: Physiological Control and Effects on Cell Proliferation." <u>Handbook Exp. Pharmacol.</u> 57:161-208 (1981)
NE	73	Clemmons et al., "Competition for Binding to Insulin-Like Growth Factor (IGF) Binding Protein-2, 3, 4, and 5 by the IGFs and IGF Analogs." <u>Endocrinology</u> , 131(2):890-895 (Aug 1992)
NE	74	Clemmons et al., "Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity." <u>J. Bio. Chem.</u> 265(21):12210-12216 (1990)
NE	75	Clemmons et al., "The Role of Insulin-Like Growth Factors in the Nervous System." <u>Anal. NY Acad. Sci. USA</u> 692:10-21 (1993)
NE	76	Clore et al., "Stereospecific Assignment of β -Methylene Protons in Larger Proteins Using 3D ^{15}N -Separated Hartmann-Hahn and ^{13}C -Separated Rotating Frame Overhauser Spectroscopy." <u>J. Biomol. NMR</u> 1:13-22 (1991)
NE	77	Cohen et al., "Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease." <u>J. Endocrinology</u> , 142:407-415 (1994)
NE	78	Cohen et al., "Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells." <u>J. Clin. Endocrin. & Metab.</u> 73:401-407 (1991)
NE	79	Cohen et al., "The IGF Axis in the Prostate." <u>Horm. & Metab. Res.</u> 26:81-84 (1994)
NE	80	Cooke et al., "Solution Structure of Human Insulin-Like Growth Factor 1: A Nuclear Magnetic Resonance and Restrained Molecular Dynamics Study" <u>Biochemistry</u> 30:5484-5491 (1991)
NE	81	Cornilescu et al., "Protein Backbone Angle Restraints From Searching a Database for Chemical Shift and Sequence Homology." <u>J. Biomol. NMR</u> 13:289-302 (1999)

Examiner

NEhed 6/

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1869R1Serial No.
10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Schaffer, M. et al.Filing Date
01 Feb 2002Group
NOT KNOWN

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

82	Culig et al., "Androgen Receptor Activation in Prostatic Tumor Cell Lines by Insulin-Like Growth Factor-I, Keratinocyte Growth Factor, and Epidermal Growth Factor." <u>Cancer Research</u> . 54:5474-5478 (1994)
83	Cullen et al., "Insulin-Like Growth Factor Receptor Expression and Function in Human Breast Cancer." <u>Cancer Research</u> . 50:48-53 (1990)
84	Daughaday and Rotwein., "Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations." <u>Endocrin. Rev.</u> 10(1):68-91 (1989)
85	De Heyts., "The Structural Basis of Insulin and Insulin-Like Growth Factor-I Receptor Binding and Negative Co-Operativity, and its Relevance to Mitogenic Versus Metabolic Signalling." <u>Diabetologia</u> . (Suppl. 2) 37:S135-S148 (1994)
86	De Wolf et al., "Solution Structure of a Mini IGF-I." <u>Protein Sci.</u> 5:2193-2202 (1996)
87	Derewenda et al., "Phenol Stabilizes More Helix in a New Symmetrical Zinc Insulin Hexamer." <u>Nature</u> . 338:594-596 (Apr 1989)
88	Dubaquie and Lowman, "Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3" <u>Biochemistry</u> 38(20):6386-6396 (1999)
89	Dubaquie et al., "Binding Protein-3-Selective Insulin-Like Growth Factor I Variants: Engineering, Biodistributions, and Clearance." <u>Endocrinology</u> . 142(1):165-173 (Jan 2001)
90	Duerr et al., "Insulin-Like Growth Factor-I Enhances Ventricular Hypertrophy and Function During the Onset of Experimental Cardiac Failure." <u>J. Clin. Invest.</u> 95:619-627 (1995)
91	Einstein and Low., "Insulin: Some Shrinkage Stages of Sulfate and Citrate Crystals." <u>Acta Crystallogr.</u> 15:32-34 (1962)
92	Elahi et al., "Hemodynamic and Metabolic Responses to Human Insulin-Like Growth Factor I (IGF-I) in Men." <u>Modern Concepts of Insulin-Like Growth Factors</u> ., Spencer, EM, ed., New York:Elsevier Science Publ. Co. pps. 219-224 (1991)
93	Fejzo et al., "The SHAPES Strategy: An NMR-Based Approach for Lead Generation in Drug Discovery." <u>Chemistry & Biology</u> . 6:755-769 (1999)
94	Feyen et al., "Recombinant Human [Cys ²⁸¹]Insulin-Like Growth Factor-Binding Protein 2 Inhibits Both Basal and Insulin-Like Growth Factor I-Stimulated Proliferation and Collagen Synthesis in Fetal Rat Calvariae." <u>J. Bio. Chem.</u> 266:19469-19474 (1991)
95	Figueroa et al., "Recombinant Insulin-Like Growth Factor Binding Protein-1 Inhibits IGF-I, Serum, and Estrogen-Dependent Growth of MCF-7 Human Breast Cancer Cells." <u>J. Cell Phys.</u> 157:229-236 (1993)
96	Froesch et al., "Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I" <u>Horm. Res.</u> 42:66-71 (1994)
97	Garrett et al., "Crystal Structure of the First Three Domains of the Type-1 Insulin-Like Growth Factor Receptor." <u>Nature</u> . 394(6691):395-399 (Jul 23, 1998)
98	Guler et al., "Recombinant Human Insulin-Like Growth Factor 1 Stimulates Growth and has Distinct Effects on Organ Size in Hypophysectomized Rats." <u>Proc. Natl. Acad. Sci. USA</u> 85:4889-4893 (1988)
99	Hammerman and Miller., "The Growth Hormone Insulin-Like Factor Axis in Kidney Revisited." <u>Am. J. Physiol.</u> 265:F1-F14 (1993)
100	Hammerman and Miller., "Therapeutic Use of Growth Factors in Renal Failure." <u>J. Am. Soc. Nephrol.</u> 5:1-11 (1994)
101	Hasegawa et al., "The Free Form of Insulin-Like Growth Factor I Increases in Circulation During Normal Human Pregnancy." <u>J. Clin. Endocrinol. Metabol.</u> 80:3284-3286 (1995)

Examiner

Noted 6/4/02

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066.009

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

NE	102	Hizuka et al., "Measurement of Free Form of Insulin-Like Growth Factor I in Human Plasma." <u>Growth Regulation</u> . 1:51-55 (1991)
NE	103	Horney et al., "Elevated Glucose Increases Mesangial Cell Sensitivity to Insulin-Like Growth Factor I." <u>Am. J. Physiol.</u> 274:F1045-F1053 (1998)
NE	104	Hsing et al., "Regulation of Apoptosis Induced by Transforming Growth Factor- β 1 in Nontumorigenic and Tumorigenic Rat Prostatic Epithelial Cell Lines." <u>Cancer Research</u> . 56:5146-5149 (1996)
NE	105	Humbel., "Insulin-Like Growth Factors I and II." <u>European Journal of Biochemistry</u> . 190:445-462 (1990)
NE	106	Huynh et al., "Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-Like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells." <u>J. Bio. Chem.</u> 271(2):1016-1021 (1996)
NE	107	Isaksson et al., "Growth Hormone Stimulates Longitudinal Bone Growth Directly." <u>Science</u> . 216:1237-1239 (1982)
NE	108	Isaksson et al., "Mechanism of the Stimulatory Effect of Growth Hormone on Longitudinal Bone Growth." <u>Endocrine Reviews</u> . 8(4):426-438 (1987)
NE	109	Iwamura et al., "Insulin-Like Growth Factor I: Action and Receptor Characterization in Human Prostate Cancer Cell Lines." <u>Prostate</u> . 22:243-252 (1993)
NE	110	Jabri et al., "Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients." <u>Diabetes</u> 43:369-374 (1994)
NE	111	Janin and Chothia., "The Structure of Protein-Protein Recognition Sites." <u>J. Bio. Chem.</u> 265(27):16027-16030 (1990)
NE	112	Jansson et al., "The Insulin-Like Growth Factor (IGF) Binding Protein 1 Binding Epitope on IGF-I Probed by Heteronuclear NMR Spectroscopy and Mutational Analysis." <u>J. Bio. Chem.</u> 273(38):24701-24707 (September 18, 1998)
NE	113	Jones and Clemmons., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions." <u>Endocrine Rev.</u> 16(1):3-34 (1995)
NE	114	Juul et al., "Serum Concentrations of Free and Total Insulin-Like Growth Factor-I, IGF Binding Proteins -1 and -3 and IGFBP-3 Protease Activity in Boys with Normal or Precocious Puberty." <u>Clin. Endocrin.</u> 44:515-523 (1996)
NE	115	Juul et al., "Serum Insulin-Like Growth Factor-I in 1030 Healthy Children, Adolescents, and Adults: Relation to Age, Sex, Stage of Puberty, Testicular Size, and Body Mass Index." <u>J. Clin. Endocrin. & Metab.</u> 78(8):744-752 (1994)
NE	116	Juul et al., "Serum Levels of Insulin-Like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3) in Healthy Infants, Children, and Adolescents: The Relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, Age, Sex, Body Mass Index, and Pubertal Maturation." <u>J. Clin. Endocrin. & Metab.</u> 80:2534-2542 (1995)
NE	117	Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans: A Comparison with Insulin." <u>J. Clin. Invest.</u> 91:141-147 (1993)
NE	118	Kuzuya et al., "Trial of Insulinlike Growth Factor I Therapy for Patients with Extreme Insulin Resistance Syndromes." <u>Diabetes</u> . 42:696-705 (1993)
NE	119	Laajoki et al., "Secondary Structure Determination of ^{15}N -Labelled Human Long-[Arg-3]-Insulin-Like Growth Factor 1 by Multidimensional NMR Spectroscopy." <u>FEBS Letters</u> 420:97-102 (1997)
NE	120	Laajoki et al., "Solution Structure and Backbone Dynamics of Long-[Arg-3]Insulin-Like Growth Factor-I." <u>J. Bio. Chem.</u> 275(14):10009-10015 (2000)
NE	121	Lee et al., "A Pulsed Field Gradient Isotope-Filtered 3D ^{13}C HMQC-NOESY Experiment for Extracting Intermolecular NOE Contacts in Molecular Complexes." <u>FEBS Letters</u> 350:87-90 (1994)

Examiner

N. Shedd 6/4/04

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

NE 122	Lee et al., "Activation of Estrogen Receptor-Mediated Gene Transcription by IGF-I in Human Breast Cancer Cells." <u>J. Endocrinol.</u> 152:39-47 (1997)
NE 123	Lee et al., "Regulation and Function of Insulin-Like Growth Factor-Binding Protein-1." <u>Proc. Soc. Exp. Biol. & Med.</u> 204:4-29 (1993)
NE 124	LeRoith et al., "Insulin-Like Growth Factors and Cancer." <u>Annals of Internal Medicine.</u> 122(1):54-59 (Jan. 1995)
NE 125	LeRoith., "Editorial: Insulin-Like Growth Factor I Receptor Signaling-- Overlapping or Redundant Pathways?" <u>Endocrinology.</u> 141(4):1287-1288 (2000)
NE 126	Lewitt and Baxter, "Insulin-Like Growth Factor-Binding Protein-1: A Role in Glucose Counterregulation?" <u>Mol. Cell. Endocrin.</u> 79(1-3):C147-C152 (1991)
NE 127	Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" <u>Endocrinology</u> 129(4):2254-2256 (1991)
NE 128	Lieberman et al., "Effects of Recombinant Human Insulin-Like Growth Factor-I (rhIGF-I) on Total and Free IGF-I Concentrations, IGF-Binding Proteins, and Glycemic Response in Humans." <u>J. Clin. Endocrinol. & Metab.</u> 75(1):30-36 (1992)
NE 129	Liu et al., "Insulin-Like Growth Factor-I Affects Perinatal Lethality and Postnatal Development in a Gene Dosage-Dependent Manner: Manipulation Using the Cre/loxP System in Transgenic Mice." <u>Molecular Endocrinology</u> 12(9):1452-1462 (1998)
NE 130	Liu et al., "Mice Carrying Null Mutations of the Genes Encoding Insulin-Like Growth Factor I (Igf-1) and Type I IGF Receptor (Igf1r)." <u>Cell.</u> 75:59-72 (Oct 1993)
NE 131	Long et al., "Loss of the Metastatic Phenotype in Murine Carcinoma Cells Expressing an Antisense RNA to the Insulin-Like Growth Factor Receptor." <u>Cancer Research.</u> 55:1006-1009 (1995)
NE 132	Lowman et al., "Molecular Mimics of Insulin-Like Growth Factor I (IGF-I) for Inhibiting IGF-1: IGF-Binding Protein Interactions." <u>Biochemistry</u> 37(25):8870-8878 (1998)
NE 133	McGuire et al., "Regulation of Insulin-Like Growth Factor-Binding Protein (IGFBP) Expression by Breast Cancer Cells: Use of IGFBP-1 as an Inhibitor of Insulin-Like Growth Factor Action." <u>J. Natl. Cancer Institute</u> 84(17):1336-1341 (1992)
NE 134	McPherson, Alexander. <u>Preparation and Analysis of Protein Crystals.</u> (Second Edition), Malabar, FL:Robert E. Krieger Publishing Comp. (1989)
NE 135	Morrow et al., "Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance" <u>Diabetes-53rd Annual Meeting, June 12-15, 1993</u> (Suppl. 1, abstract No. 269) 42:83A (1993)
NE 136	Oh et al., "Antiproliferative Actions of Insulin-Like Growth Factor Binding Protein (IGFBP)-3 in Human Breast Cancer Cells." <u>Prog. Growth Factor Res.</u> 6(2-4):503-512 (1995)
NE 137	Oh et al., "Characterization of the Affinities of Insulin-Like Growth Factor (IGF)-Binding Proteins 1-4 for IGF-I, IGF-II, IGF-I/Insulin Hybrid, and IGF-I Analogs." <u>Endocrinology.</u> 132:1337-1344 (1993)
NE 138	Oh et al., "Insulin-Like Growth Factor (IGF)-Independent Action of IGF-Binding Protein-3 in Hs578T Human Breast Cancer Cells." <u>J. Bio. Chem.</u> 268(20):14964-14971 (1993)
NE 139	Peterkofsky et al., "Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs" <u>Endocrinology</u> 128(4):1769-1779 (1991)
NE 140	Pietrzkowski et al., "Inhibition of Cellular Proliferation by Peptide Analogues of Insulin-Like Growth Factor 1." <u>Cancer Research.</u> 52:6447-6451 (1992)
NE 141	Powell-Braxton et al., "IGF-I is Required for Normal Embryonic Growth in Mice." <u>Genes Dev.</u> 7:2609-2617 (1993)

Examiner

N. Smith 6/4/04

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1869R1Serial No.
10/066,009

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Schaffer, M. et al.Filing Date
01 Feb 2002Group
NOT KNOWN

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

142	Pratt and Pollak., "Insulin-Like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation." <u>Biophys. Res. Comm.</u> 198(1):292-297 (1994)
143	Quin et al., "Acute Response to Recombinant Insulin-Like Growth Factor I in a Patient with Mendenhall's Syndrome." <u>New Engl. J. Med.</u> 323(20):1425-1426 (1990)
144	Quinn et al., "Insulin-Like Growth Factor Expression in Human Cancer Cell Lines." <u>J. Bio. Chem.</u> 271(19):11477-11483 (1996)
145	Rajah et al., "Insulin-Like Growth Factor (IGF)-Binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor- β 1 on Programmed Cell Death through a p53- and IGF-Independent Mechanism." <u>J. Bio. Chem.</u> 272(18):12181-12188 (1997)
146	Reilly and Fairbrother., "A Novel Isotope Labeling Protocol for Bacterially Expressed Proteins." <u>J. Biomol. NMR</u> 4:459-462 (1994)
147	Rinderknecht and Humbel., "Amino-Terminal Sequences of Two Polypeptides From Human Serum with Nonsuppressible Insulin-Like and Cell-Growth-Promoting Activities: Evidence for Structural Homology with Insulin B Chain." <u>Proc. Natl. Acad. Sci. USA</u> 73(12):4379-4381 (1976)
148	Rinderknecht and Humbel., "The Amino Acid Sequence of Human Insulin-Like Growth Factor I and Its Structural Homology with Proinsulin." <u>Journal of Biological Chemistry</u> 253(8):2769-2776 (1978)
149	Rohlik et al., "An Antibody to the Receptor for Insulin-Like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture." <u>Biochem. & Biophys. Res. Comm.</u> 149(1):276-281 (Nov 1987)
150	Saad et al., "Low-Doses of Insulin-Like Growth Factor-I Improve Insulin Sensitivity." <u>Diabetologia</u> . (Abstract 152) 37:A40 (Supp. 1 1994)
151	Sato et al., "Three-Dimensional Structure of Human Insulin-Like Growth Factor-I (IGF-I) Determined by ¹ H-NMR and Distance Geometry." <u>Int. J. Pep. Protein Res.</u> 41:433-440 (1993)
152	Schalch et al., "Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Metabolic Control of Patients with Type II Diabetes Mellitus" <u>J. of Clinical Endocrinology & Metabolism</u> 77(6):1563-1568 (1993)
153	Schalch et al., "Short-Term Metabolic Effects of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I) in Type II Diabetes Mellitus." <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, ed., New York:Elsevier Science Publ. Co. pps. 705-713 (1991)
154	Schlechter et al., "Evidence Suggesting that the Direct Growth-Promoting Effect of Growth Hormone on Cartilage In Vivo is Mediated by Local Production of Somatomedin." <u>Proc. Natl. Acad. Sci. USA</u> 83:7932-7934 (1986)
155	Schoenle et al., "Recombinant Human Insulin-Like Growth Factor I (rhIGF I) Reduces Hyperglycaemia in Patients with Extreme Insulin Resistance." <u>Diabetologia</u> . 34:675-679 (1991)
156	Sjogren et al., "Liver-Derived Insulin-Like Growth Factor I (IGF-I) is the Principal Source of IGF-I in Blood but is Not Required for Postnatal Body Growth in Mice." <u>Proc. Natl. Acad. Sci. USA</u> 96:7088-7092 (1999)
157	Smith et al., "Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization." <u>Science</u> . 276:1706-1709 (1997)
158	Steller et al., "Overexpression of the Insulin-Like Growth Factor-1 Receptor and Autocrine Stimulation in Human Cervical Cancer Cells." <u>Cancer Research</u> . 56:1761-1765 (1996)
159	Stracke et al., "The Type I Insulin-Like Growth Factor Receptor is a Motility Receptor in Human Melanoma Cells." <u>J. Bio. Chem.</u> 264(36):21544-21549 (Dec 1989)
160	Suikkari et al., "Insulin Regulates the Serum Levels of Low Molecular Weight Insulin-Like Growth Factor-Binding Protein." <u>J. Clin. Endocrin. Metabol.</u> 66:266-272 (1988)
161	Tollefsen and Thompson., "The Structural Basis for Insulin-Like Growth Factor I Receptor High Affinity Binding." <u>J. Bio. Chem.</u> 263(31):16267-16273 (1988)

Examiner

N. Steed 6/4/04

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce
Patent and Trademark Office

Serial No.
10/066,009

Applicant
Schaffer, M. et al.

Filing Date
01 Feb 2002

Group
NOT KNOWN

NR	162	Torres et al., "Solution Structure of Human Insulin-Like Growth Factor II: Relationship to Receptor and Binding Protein Interactions." <u>J. Mol. Bio.</u> 248(2):385-401 (Apr 28, 1995)
NR	163	Usala et al., "Brief Report: Treatment of Insulin-Resistant Diabetic Ketoacidosis with Insulin-Like Growth Factor I in an Adolescent with Insulin-Dependent Diabetes." <u>New Engl. J. Med.</u> 327(12):853-857 (1992)
NR	164	Vajdos et al., "Crystal Structure of Human Insulin-Like Growth Factor-1: Detergent Binding Inhibits Binding Protein Interactions." <u>Biochemistry</u> 40:11022-11029 (2001)
NR	165	Valentinis et al., "The Human Insulin-Like Growth Factor (IGF) Binding Protein-3 Inhibits the Growth of Fibroblasts with a Targeted Disruption of the IGF-I Receptor Gene." <u>Molecular Endocrinology</u> , 9:361-367 (1995)
NR	166	Van Holde., "X-Ray Diffraction." <u>Physical Biochemistry</u> , NJ:Prentice Hall, Chapter 11, pps. 221-239 (1971)
	167	Van Wyk et al., "The Somatomedins: A Family of Insulinlike Hormones Under Growth Hormone Control " Recent Prog. Horm. Res. 30:259-318 (1974) <i>Reference is not in the file</i>
NR	168	Vlachopapadopoulou et al., "Metabolic and Clinical Response to Recombinant Human Insulin-like Growth Factor I in Myotonic Dystrophy - A Clinical Research Center Study" <u>J. Clin. Endo. Metab.</u> 80(12):3715-3723 (1995)
NR	169	Weber., "Physical Principles of Protein Crystallization." <u>Advances in Protein Chemistry</u> , 41:1-36 (1991)
NR	170	Yee et al., "Insulin-Like Growth Factor Binding Protein 1 Expression Inhibits Insulin-Like Growth Factor I Action in MCF-7 Breast Cancer Cells." <u>Cell Growth & Diff.</u> 5:73-77 (1994)
NR	171	Zenobi et al., "Effects of Insulin-Like Growth Factor-I on Glucose Tolerance, Insulin Levels, and Insulin Secretion." <u>J. Clin. Invest.</u> 89:1908-1913 (1992)
NR	172	Zenobi et al., "Insulin-Like Growth Factor-I Improves Glucose and Lipid Metabolism in Type 2 Diabetes Mellitus." <u>J. Clin. Invest.</u> 90:2234-2241 (1992)
NR	173	Zeslawski et al., "The Interaction of Insulin-Like Growth Factor-I with the N-Terminal Domain of IGFBP-5." <u>EMBO Journal</u> , 20(14):3638-3644 (2001)

Examiner Noted 6/4/04

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.